Cibus share price today

(CBUS)

Cibus share price is $2.69 & ₹229.18 as on 25 Dec 2024, 2.30 'hrs' IST

$2.69

▲

-0.15

(-5.28%)

Market is closed - opens 8 PM, 26 Dec 2024

View live Cibus share price in Dollar and Rupees. Guide to invest in Cibus from India. Also see the sentimental analysis on Indian investors investing in Cibus. Get details on the Indian mutual funds that are investing in Cibus. Get Analyst recommendations and forecasts along with all the Cibus's financials.

Cibus share price movements

Today's Low: $2.62
Today's High: $2.85
$2.69
2.6%
Downside
Day's Volatility :8.07%
Upside
5.61%
52 Weeks Low: $2.37
52 Weeks High: $23.18
$2.69
11.9%
Downside
52 Weeks Volatility :89.78%
Upside
88.4%

Cibus Returns

Period	Cibus Inc	Index (Russel 2000)
3 Months	-21.11%	0.0%
6 Months	-71.65%	0.0%
1 Year	-87.03%	0.0%
3 Years	-89.67%	-21.1%

Cibus Key Statistics

in dollars & INR

Previous Close	$2.84
Open	$2.82
Today's High	$2.85
Today's Low	$2.62
Market Capitalization	$79.5M
Today's Volume	$195.9K
52 Week High	$23.18
52 Week Low	$2.37
Revenue TTM	$4.2M
EBITDA	$-60.3M
Earnings Per Share (EPS)	$-45.95
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-149.74%

How to invest in Cibus from India?

It is very easy for Indian residents to invest directly in Cibus from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Cibus stock in both Indian Rupees (INR) and US Dollars (USD). Search for Cibus or CBUS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Cibus or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Cibus shares which would translate to 0.317 fractional shares of Cibus as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Cibus, in just a few clicks!

Returns in Cibus for Indian investors in Rupees

Investment Value

₹1,00,000

Cibus investment value today

Current value as on today

₹15,209

Returns

₹84,791

(-84.79%)

Returns from Cibus Stock

₹87,030 (-87.03%)

Dollar Returns

₹2,239 (+2.24%)

Indian investors sentiment towards Cibus

-15%

Period: Sep 26, 2024 to Dec 25, 2024. Change in 30 Days versus previous period

Search volume for Cibus on INDmoney from India has reduced in the last 30 days as on Dec 26, 2024. -15% less investors are searching Cibus in the last 30 days versus the previous period.

Analyst Recommendation on Cibus

Buy

77%Buy

22%Hold

0%Sell

Based on 9 Wall street analysts offering stock ratings for Cibus(by analysts ranked 0 to 5 stars)

Based on 9 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Cibus

What analysts predicted

Upside of 573.79%

Current:

$2.69

Target:

$18.13

Insights on Cibus

Price Movement
In the last 7 days, CBUS stock has moved down by -3.9%
Increasing Revenue
Revenue is up for the last 3 quarters, 545.0K → 1.66M (in $), with an average increase of 42.4% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -23.43M → -179.96M (in $), with an average decrease of 314.7% per quarter
CBUS vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 27.2% return, outperforming this stock by 113.8%
Price to Sales
ForCBUS every $1 of sales, investors are willing to pay $13.5, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.7 for every $1 of sales.

Cibus Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$236.0K	↓ 53.54%
Net Income	$-27.9M	↑ 7.38%
Net Profit Margin	-11.8K%	↓ 6706.59%

	FY19	Y/Y Change
Revenue	$7.3M	↑ 2991.53%
Net Income	$-39.6M	↑ 41.99%
Net Profit Margin	-542.93%	↑ 11277.83%

	FY20	Y/Y Change
Revenue	$23.9M	↑ 226.91%
Net Income	$-44.8M	↑ 13.19%
Net Profit Margin	-187.98%	↑ 354.95%

	FY21	Y/Y Change
Revenue	$26.0M	↑ 8.96%
Net Income	$-29.2M	↓ 34.88%
Net Profit Margin	-112.36%	↑ 75.62%

	FY22	Y/Y Change
Revenue	$157.0K	↓ 99.4%
Net Income	$-16.9M	↓ 42.15%
Net Profit Margin	-10.8K%	↓ 10646.24%

	FY23	Y/Y Change
Revenue	$1.8M	↑ 1057.32%
Net Income	$-267.6M	↑ 1484.44%
Net Profit Margin	-14.7K%	↓ 3970.46%

	Q2 FY23	Q/Q Change
Revenue	$197.0K	↑ 369.05%
Net Income	$-20.5M	↑ 280.22%
Net Profit Margin	-10.4K%	↑ 2432.2%

	Q3 FY23	Q/Q Change
Revenue	$475.0K	↑ 141.12%
Net Income	$-34.5M	↑ 68.36%
Net Profit Margin	-7.3K%	↑ 3141.61%

	Q4 FY23	Q/Q Change
Revenue	$1.1M	↑ 132.21%
Net Income	$-207.2M	↑ 500.08%
Net Profit Margin	-18.8K%	↓ 11515.72%

	Q1 FY24	Q/Q Change
Revenue	$545.0K	↓ 50.59%
Net Income	$-23.4M	↓ 88.69%
Net Profit Margin	-4.3K%	↑ 14484.77%

	Q2 FY24	Q/Q Change
Revenue	$838.0K	↑ 53.76%
Net Income	$-24.9M	↑ 6.18%
Net Profit Margin	-3.0K%	↑ 1330.67%

	Q3 FY24	Q/Q Change
Revenue	$1.7M	↑ 98.93%
Net Income	$-180.0M	↑ 623.26%
Net Profit Margin	-10.8K%	↓ 7826.59%

	FY18	Y/Y Change
Profit	$-845.0K	↑ 1865.12%

	FY19	Y/Y Change
Profit	$-2.0M	↑ 134.79%

	FY20	Y/Y Change
Profit	$-11.3M	↑ 468.35%

	FY21	Y/Y Change
Profit	$-2.6M	↓ 77.21%

	FY22	Y/Y Change
Profit	$157.0K	↓ 106.11%

	FY23	Y/Y Change
Profit	$1.4M	↑ 805.73%

	Q2 FY23	Q/Q Change
Profit	$-529.0K	↑ 19.14%

	Q3 FY23	Q/Q Change
Profit	$-1.2M	↑ 128.54%

	Q4 FY23	Q/Q Change
Profit	$1.0M	↓ 185.36%

	Q1 FY24	Q/Q Change
Profit	$-1.2M	↓ 218.41%

	Q2 FY24	Q/Q Change
Profit	$-895.0K	↓ 26.76%

	Q3 FY24	Q/Q Change
Profit	$1.7M	↓ 286.26%

	FY19	Y/Y Change
Operating Cash Flow	$-32.0M	↑ 57.77%
Investing Cash Flow	$-3.0M	-
Financing Cash Flow	$-330.0K	↓ 100.54%

	FY20	Y/Y Change
Operating Cash Flow	$-43.7M	↑ 36.68%
Investing Cash Flow	$-13.5M	↑ 354.16%
Financing Cash Flow	$15.4M	↓ 4768.79%

	FY21	Y/Y Change
Operating Cash Flow	$-18.8M	↓ 56.93%
Investing Cash Flow	$11.2M	↓ 183.07%
Financing Cash Flow	$3.7M	↓ 75.71%

	FY22	Y/Y Change
Operating Cash Flow	$-19.4M	↑ 2.94%
Investing Cash Flow	$-1.5M	↓ 113.57%
Financing Cash Flow	$10.0M	↑ 166.94%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-11.7M	↑ 394.48%
Investing Cash Flow	$58.8M	↑ 0.0%
Financing Cash Flow	$1.8M	↑ 94.8%

Cibus Technicals Summary

Sell

Neutral

Buy

Cibus is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Cibus Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Cibus Inc	-40.09%	-71.65%	-87.03%	-89.67%	-89.67%
Regeneron Pharmaceuticals, Inc.	-5.12%	-32.01%	-18.29%	12.56%	91.19%
Biontech Se	-3.72%	41.99%	6.11%	-55.22%	226.93%
Alnylam Pharmaceuticals, Inc.	-3.99%	-1.52%	23.75%	50.98%	112.09%
Vertex Pharmaceuticals Incorporated	-12.61%	-13.61%	0.03%	83.58%	86.41%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Cibus Inc	NA	NA	NA	-5.27	-1.5	-0.07	NA	4.09
Regeneron Pharmaceuticals, Inc.	17.67	17.67	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.06	0.51	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Cibus Inc	Buy	$79.5M	-89.67%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$78.5B	91.19%	17.67	33.61%
Biontech Se	Buy	$27.4B	226.93%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$31.4B	112.09%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$105.1B	86.41%	32.84	-4.51%

About Cibus

Organization	Cibus
Employees	183
CEO	Mr. Rory Balfour Riggs M.B.A.
Industry	Chemicals: Agricultural

Management People of Cibus

Name	Title
Mr. Rory Balfour Riggs M.B.A.	Co-Founder, CEO & Chairman
Dr. Peter Beetham B.Sc., Ph.D.	Co-Founder, President, COO & Director
Dr. Greg Gocal Ph.D.	Co-Founder, Chief Scientific Officer & Executive VP
Mr. Jason Stokes J.D.	Chief Legal Officer, General Counsel & Corporate Secretary
Ms. Rosa Cheuk Kim J.D.	Senior Vice President of Legal
Dr. James Radtke Ph.D.	Senior Vice President of Product Development
Mr. Tony Moran	Senior Vice President of International Development
Norm Sissons	Senior Vice President of Seed & Traits
Ms. Noel Sauer Ph.D.	Senior Vice President of Research
Mr. Sean O'Connor Ph.D.	Senior VP and President & CEO of Nucelis

Important FAQs about investing in Cibus from India :

What is Cibus share price today?

Cibus share price today stands at $2.69, Open: $2.82 ; Previous Close: $2.84 ; High: $2.85 ; Low: $2.62 ; 52 Week High: $23.18 ; 52 Week Low: $2.37. The stock opens at $2.82, after a previous close of $2.84. The stock reached a daily high of $2.85 and a low of $2.62, with a 52-week high of $23.18 and a 52-week low of $2.37.

Can Indians buy Cibus shares?

Yes, Indians can invest in the Cibus (CBUS) from India.

With INDmoney, you can buy Cibus at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Cibus at zero transaction cost.

How can I buy Cibus shares from India?

It is very easy to buy Cibus from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Cibus be purchased?

Yes, you can buy fractional shares of Cibus with INDmoney app.

What are the documents required to start investing in Cibus stocks?

To start investing in Cibus, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.